Form 4: UTHR CEO Executes Pre-Arranged Stock Sales
Insider Transaction Report
United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock totaling 8,000 shares over two days.
Summary
- Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (UTHR), reported transactions on December 3 and December 4, 2025.
- These transactions were conducted under a Rule 10b5-1 trading plan established on May 2, 2025.
- On December 3, 2025, 4,000 common stock options were exercised at a price of $120.26 per share.
- On December 3, 2025, a total of 4,000 common shares were sold in multiple trades at weighted average prices of $474.1011, $475.4338, and $476.2577.
- On December 4, 2025, an additional 4,000 common stock options were exercised at a price of $120.26 per share.
- On December 4, 2025, a total of 4,000 common shares were sold in multiple trades at weighted average prices of $478.9271 and $480.5975.
- Following these reported transactions, direct beneficial ownership of common stock is 130 shares.
- Indirect beneficial ownership includes 166 shares held by a spouse and 324,518, 258,117, 45,596, and 15,962 shares held in various family trusts.
- The 10b5-1 plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
- After these exercises, 42,000 stock options remain subject to the plan.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions executed under a pre-arranged 10b5-1 plan, which is generally considered neutral. The significant profit margin on the exercised options is positive for the insider, but the act of selling itself is a common personal financial management activity.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and compliant approach to insider trading.
- Significant gains were realized from the sale of shares at prices ranging from $474.10 to $480.60, compared to the exercise price of $120.26 per share.
Negatives
- The sale of common stock by a high-ranking insider, even under a pre-arranged plan, can sometimes be perceived negatively by some investors, though it is often for personal financial planning or diversification.
Future Outlook
The filing does not provide forward-looking statements or guidance regarding the company's future performance, only details about the continuation of the insider's pre-arranged trading plan.
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Implementation | The transactions were executed under a Rule 10b5-1 trading plan, established on May 2, 2025, which is a corporate governance mechanism designed to prevent accusations of insider trading based on material non-public information. | 2025-05-02 | Enhances transparency and compliance regarding insider stock transactions, aligning with best practices for corporate governance. |
Related Party Transactions
- Indirect beneficial ownership includes shares held by the reporting person's spouse and various family trusts, as detailed in the filing. These are ownership structures, not transactions in the typical sense of related party dealings.
Stakeholder Impact
- Shareholders: The routine nature of these sales under a 10b5-1 plan typically has minimal direct impact on shareholder sentiment, as it's a pre-planned personal financial activity rather than a signal of management's view on future company performance.
Next Steps
- The pre-arranged 10b5-1 trading plan will continue until the earlier of the exhaustion of the remaining 42,000 stock options or December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| 2020-03-15 | Date stock options became exercisable. |
| 2025-03-15 | Expiration date for a tranche of 294,000 stock options. |
| 2025-05-02 | Date the pre-arranged 10b5-1 trading plan was entered into. |
| 2025-12-03 | Date of stock option exercise and subsequent sale transactions. |
| 2025-12-04 | Date of additional stock option exercise and subsequent sale transactions. |
| 2025-12-05 | Date the Form 4 filing was signed. |
| 2025-12-31 | Earlier of the two dates for the 10b5-1 plan to conclude. |
| 2026-03-15 | Expiration date for the remaining stock options under the 10b5-1 plan. |
Keywords
United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.